Roche, Meiji & Fedora next in line to combat superbugs with antibiotics booster

Roche makes its next move in antibiotic research with its licensing deal with Meiji Seika Pharma and Canada’s Fedora. The deal, worth up to $750 million, allows Roche the right to develop and commercialize beta-lactamase inhibitor OP0595 internationally, with exception to Japan. Meiji gets to keep its sole rights. Beta-lactamase inhibitors restore or potentiate the activity of beta-lactam antibiotics. The …